Douglas F. Kling

Insider Reports History

Location
C/O Matinas Biopharma Holdings, Inc., 1545 Route 206 South, Suite 302, Bedminster, NJ
Signature
/s/ Louise Kooij by Power of Attorney from Douglas F. Kling
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Douglas F. Kling:

Stock Role Class Num Shares Value Price $ Report Date Ownership
NewAmsterdam Pharma Co N.V. Chief Operating Officer Ordinary Shares 44K $928K $21.10 Jul 16, 2025 Direct
NewAmsterdam Pharma Co N.V. Chief Operating Officer Option (right to buy) 163K Jul 16, 2025 Direct
NewAmsterdam Pharma Co N.V. Chief Operating Officer Restricted Stock Unit 0 Mar 26, 2025 Direct

Insider Reports Filed by Douglas F. Kling

Symbol Company Period Transactions Value $ Form Type Date Filed Role
NAMS NewAmsterdam Pharma Co N.V. Jul 15, 2025 7 -$1.02M 4 Jul 17, 2025 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. Jun 16, 2025 6 -$909K 4 Jun 18, 2025 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. May 15, 2025 3 $1M 4 May 19, 2025 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. Apr 15, 2025 4 $1M 4 Apr 17, 2025 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. Mar 26, 2025 4 $0 4 Mar 28, 2025 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. Mar 17, 2025 5 $119K 4 Mar 19, 2025 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. Feb 18, 2025 6 $0 4 Feb 20, 2025 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. Jan 29, 2025 7 $0 4 Jan 31, 2025 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. Jan 27, 2025 8 $0 4 Jan 29, 2025 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. Jan 7, 2025 1 $0 4 Jan 7, 2025 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. Jan 2, 2025 1 $0 4 Jan 6, 2025 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. Jan 1, 2024 1 $0 4 Jan 3, 2024 Chief Operating Officer
NAMS NewAmsterdam Pharma Co N.V. Dec 29, 2023 0 $0 3 Dec 29, 2023 Chief Operating Officer